ImpriMed, which builds AI-powered drug response prediction tech to help treat cancer in dogs and cats, raised a $23M Series A led by SoftBank Ventures Asia — ImpriMed, a California-based precision medicine startup, builds AI-powered dog cancer treatment technology that helps veterinarians identify …
Posted from: this blog via Microsoft Power Automate.